Bevacizumab directly into brain arteries for recurrent brain tumors
Treatments studied
Part of Cancer clinical trials.
This early-stage trial tests whether giving a targeted cancer medicine (bevacizumab) directly into brain arteries can help shrink or control certain recurrent (coming back) brain tumors. It may be an option if standard treatments are no longer working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your diagnosis is a confirmed recurrent brain tumor such as glioblastoma, anaplastic astrocytoma, or anaplastic mixed oligoastrocytoma (confirmed by pathology/biopsy).
- You have at least one tumor spot that can be confirmed—ideally proven by biopsy.
- You are well enough to participate: Karnofsky 70% or ECOG 0–2 (meaning you’re able to do most daily activities).
- If you can become pregnant, you must use effective birth control during treatment and for 3 months after.
- You have NOT had more than 2 prior treatment cycles of bevacizumab at 10 mg/kg (about two IV infusions).
- You are not pregnant or breastfeeding.
- You do not have other serious medical or mental health problems that would make treatment or follow-up unsafe or hard to complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This trial studies giving cetuximab (a targeted antibody) directly into an artery along with repeat radiation to treat certain recurring or treatment-resistant brain tumors. It may help by delivering the drug more directly to tumor areas and testing whether this approach can control the disease after it comes back.
This study tests whether adding focused ultrasound to the standard drug Avastin (bevacizumab) can help treat recurrent glioblastoma. The ultrasound may help more of the drug reach the tumor.
This Phase 1/2 study tests whether giving cetuximab directly into the artery that feeds the brain tumor can help people with newly diagnosed glioblastoma. It aims to target the tumor more precisely while checking safety and early signs of benefit.
This trial tests whether giving bevacizumab (a drug that blocks blood vessel growth) before surgery helps treat newly diagnosed high-grade gliomas. It may be an option for adults who have not had prior anti-angiogenic therapy.
This trial tests whether using special MRI information to plan proton radiation, plus a drug called Avastin (bevacizumab), can help control recurrent glioblastoma (a fast-growing brain tumor) and improve outcomes. It mainly aims to treat tumor that has come back after prior standard radiation, using careful timing and imaging to target it safely.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.